Diabetic Neuropathy - Pipeline Review, H1 2015

Diabetic Neuropathy - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Diabetic Neuropathy - Pipeline Review, H1 2015’, provides an overview of the Diabetic Neuropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Neuropathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Diabetic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Diabetic Neuropathy Overview
Therapeutics Development
Pipeline Products for Diabetic Neuropathy - Overview
Pipeline Products for Diabetic Neuropathy - Comparative Analysis
Diabetic Neuropathy - Therapeutics under Development by Companies
Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes
Diabetic Neuropathy - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Diabetic Neuropathy - Products under Development by Companies
Diabetic Neuropathy - Products under Investigation by Universities/Institutes
Diabetic Neuropathy - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Araim Pharmaceuticals Inc.
Astellas Pharma Inc.
Cebix Incorporated
Eli Lilly and Company
Glucox Biotech AB
Longevity Biotech, Inc
Lpath, Inc.
Neuralstem, Inc.
Omeros Corporation
Pfizer Inc.
R-Tech Ueno, Ltd.
Spinifex Pharmaceuticals Pty Limited
Sumitomo Dainippon Pharma Co., Ltd.
Virobay Inc.
ViroMed Co., Ltd.
Diabetic Neuropathy - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antimunocel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARA-290 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ASP-8477 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BBI-21007 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologic for Diabetic Nephropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BNV-222 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
capsaicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CBX-129801 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyndacel-M - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug for Peripheral Neuropathic Pain and Diabetic Peripheral Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EMA-401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ketoprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NRD-135SE1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NSI-566 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OMS-721 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-05089771 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ranirestat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTU-1096 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Diabetic Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptides for Central Nervous System Disorders and Diabetic Neuropathy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VM-202 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Diabetic Neuropathy - Recent Pipeline Updates
Diabetic Neuropathy - Dormant Projects
Diabetic Neuropathy - Discontinued Products
Diabetic Neuropathy - Product Development Milestones
Featured News & Press Releases
Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy
Sep 12, 2011: Spinifex Pharmaceuticals Presents New Data On EMA401 In Model Of Diabetic Neuropathy At 21st Annual NEURODIAB Meeting
Sep 07, 2011: Cebix To Chair Symposium On C-Peptide And Pathophysiology Of Diabetes At EASD Annual Meeting
May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications
Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial
Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy
Sep 29, 2005: Dainippon And Eisai Signs Licensing Agreement For A Potential New Treatment For Diabetic Neuropathy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Diabetic Neuropathy, H1 2015
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2015
Diabetic Neuropathy - Pipeline by Acorda Therapeutics, Inc., H1 2015
Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals Inc., H1 2015
Diabetic Neuropathy - Pipeline by Astellas Pharma Inc., H1 2015
Diabetic Neuropathy - Pipeline by Cebix Incorporated, H1 2015
Diabetic Neuropathy - Pipeline by Eli Lilly and Company, H1 2015
Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H1 2015
Diabetic Neuropathy - Pipeline by Longevity Biotech, Inc, H1 2015
Diabetic Neuropathy - Pipeline by Lpath, Inc., H1 2015
Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H1 2015
Diabetic Neuropathy - Pipeline by Omeros Corporation, H1 2015
Diabetic Neuropathy - Pipeline by Pfizer Inc., H1 2015
Diabetic Neuropathy - Pipeline by R-Tech Ueno, Ltd., H1 2015
Diabetic Neuropathy - Pipeline by Spinifex Pharmaceuticals Pty Limited, H1 2015
Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015
Diabetic Neuropathy - Pipeline by Virobay Inc., H1 2015
Diabetic Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H1 2015
Diabetic Neuropathy - Dormant Projects, H1 2015
Diabetic Neuropathy - Dormant Projects (Contd..1), H1 2015
Diabetic Neuropathy - Dormant Projects (Contd..2), H1 2015
Diabetic Neuropathy - Dormant Projects (Contd..3), H1 2015
Diabetic Neuropathy - Discontinued Products, H1 2015
Diabetic Neuropathy - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Diabetic Neuropathy, H1 2015
Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook